Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X, Wang B, Chen C, Jiang Z, Hu C, Wu H, Zhang Y, Liu X, Wang W, Wang J, Hu Z, Wang A, Huang T, Liu Q, Wang W, Wang L, Wang W, Ren T, Li L, Xia R, Ge J, Liu Q, Liu J. Liu X, et al. Among authors: huang t. Eur J Med Chem. 2018 Dec 5;160:61-81. doi: 10.1016/j.ejmech.2018.10.007. Epub 2018 Oct 5. Eur J Med Chem. 2018. PMID: 30317026
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q. Wang B, et al. Among authors: huang t. Eur J Med Chem. 2018 Oct 5;158:896-916. doi: 10.1016/j.ejmech.2018.09.025. Epub 2018 Sep 13. Eur J Med Chem. 2018. PMID: 30253346
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Wu J, Wang A, Li X, Chen C, Qi Z, Hu C, Wang W, Wu H, Huang T, Zhao M, Wang W, Hu Z, Liu Q, Wang B, Wang L, Li L, Ge J, Ren T, Xia R, Liu J, Liu Q. Wu J, et al. Among authors: huang t. Cancer Biol Ther. 2019;20(6):877-885. doi: 10.1080/15384047.2019.1579958. Epub 2019 Mar 20. Cancer Biol Ther. 2019. PMID: 30894066 Free PMC article.
Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences.
Wang A, Sun Y, Liu Q, Wu H, Liu J, He J, Yu J, Chen QQ, Ge Y, Zhang Z, Hu C, Chen C, Qi Z, Zou F, Liu F, Hu J, Zhao M, Huang T, Wang B, Wang L, Wang W, Wang W, Ren T, Liu J, Sun Y, Fan S, Wu Q, Liang C, Sun L, Su B, Wei W, Liu Q. Wang A, et al. Among authors: huang t. Mol Biomed. 2020;1(1):14. doi: 10.1186/s43556-020-00018-9. Epub 2020 Nov 30. Mol Biomed. 2020. PMID: 34765997 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 35006425
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.
Yang J, Weisberg EL, Qi S, Ni W, Mei H, Wang Z, Meng C, Zhang S, Hou M, Qi Z, Wang A, Jiang Y, Jiang Z, Huang T, Liu Q, Magin RS, Doherty L, Wang W, Liu J, Buhrlage SJ, Liu Q, Griffin JD. Yang J, et al. Among authors: huang t. Leukemia. 2022 Apr;36(4):1048-1057. doi: 10.1038/s41375-021-01494-w. Epub 2022 Jan 17. Leukemia. 2022. PMID: 35034955
TAB2 scaffolds TAK1 and NLK in repressing canonical Wnt signaling.
Li M, Wang H, Huang T, Wang J, Ding Y, Li Z, Zhang J, Li L. Li M, et al. Among authors: huang t. J Biol Chem. 2010 Apr 30;285(18):13397-404. doi: 10.1074/jbc.M109.083246. Epub 2010 Mar 1. J Biol Chem. 2010. PMID: 20194509 Free PMC article.
15,527 results
You have reached the last available page of results. Please see the User Guide for more information.